Chemotherapy for ovarian cancer: an evidence-based approach
Geisler, J.P.; Manahan, K.J.; Wiemann, M.C.
Minerva Ginecologica 56(6): 539-545
2004
ISSN/ISBN: 0026-4784 PMID: 15729206 Document Number: 571102
Although cytoreductive surgery is the most influential factor in treatment for ovarian cancer, chemotherapy is needed for almost all patients diagnosed with this disease. The mainstay of chemotherapy is platinum. Different platinum compounds are used for different histologies, and different combinations are used for different histologies also. We will present the data so that each reader can understand the knowledge behind chemotherapy decisions.
Document emailed within 1 workday
Related Documents
Lucey, C.; Westphal, J.R. 1998: New approach to administrative medical decision-making: evidence-based medicine using high dose chemotherapy/bone marrow transplant for breast cancer Southern Medical Journal 91(2): 196-201Djordjevic, B.; Stojanovic, S.; Conic, I.; Jankovic-Velickovic, L.; Vukomanovic, P.; Zivadinovic, R.; Vukadinovic, M. 2012: Current approach to epithelial ovarian cancer based on the concept of cancer stem cells Journal of BUON: Official Journal of the Balkan Union of Oncology 17(4): 627-636
Welch, R.S.; James, R.D.; Wilkinson, P.M.; Belli, F.; Cowan, R.A. 1995: Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer Cancer Journal from Scientific American 1(4): 261-266
Sagawa, T.; Yamashita, K.; Kawamura, M.; Shimizu, T.; Haga, H.; Yorozu, Y.; Kasamo, M.; Fujita, M. 1985: Chemotherapy of ovarian cancer based on in vitro (HTCA) and in vivo (nude mice) chemosensitivity testing Nihon Sanka Fujinka Gakkai Zasshi 37(7): 1197-1204
Chepyala, P.; Aduli, F.; Olden, K.W. 2008: Primary prevention of colorectal cancer: an evidence-based approach Journal of the Arkansas Medical Society 104(12): 290-292
Kothandaraman, N.; Bajic, V.B.; Loganath, A.; Koh, S.; Ng, J.; Choolani, M.; Razvi, K. 2004: Early detection of epithelial ovarian cancer using a proteomics-based protein-profiling approach combined with a novel selection strategy Annals of the Academy of Medicine Singapore 33(5 Suppl): S59-S60
Nishikawa, A.; Hashimoto, H.; Takeda, M.; Kontani, K.; Miyatake, T.; Mimura, M.; Nagamatsu, M.; Yokoi, T. 2016: Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy European Journal of Gynaecological Oncology 37(4): 451-454
Du Bois, A.; Lück, H.J.; Meier, W.; Möbus, V.; Costa, S.; Richter, B.; Warm, M.; Bauknecht, T.; Schröder, W.; Olbricht, S.; Nitz, U.; Jackisch, C. 1997: Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase IIi trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group Seminars in Oncology 24(5 Suppl 15: S15
Fulcher, M. 2016: The efficacy of sexuality education for the whole person and all people: An evidence-based approach. Review of Evidence-based approaches to sexuality education: a global perspective Psychology of Sexual Orientation and Gender Diversity 3(2): 257-258
Reynolds, T.M.; Wierzbicki, A.S. 2003: Does evidence-based medicine provide evidence? The evidence on breast cancer and the safety of oral contraceptives suggests that unorthodox interpretations may be just as valid Breast Journal 9(1): 66-67
Hong, R.; Ma, F.; Shi, X.; Li, Q.; Zhang, P.; Yuan, P.; Wang, J.; Fan, Y.; Cai, R.; Li, Q.; Xu, B. 2014: Comparison of the effectiveness of platinum-based chemotherapy versus non-platinum-based chemotherapy for triple-negative breast cancer with metastases confined to the lungs Zhonghua Zhong Liu Za Zhi 36(10): 788-792
Murakami, F.; Kiyozuka, Y.; Nishimura, H.; Imamura, K.; Yakushiji, M.; Noda, T.; Adachi, S.; Ito, K.; Tamori, N.; Shintani, M. 1993: Etoposide/cis-platinum (CDDP) combined chemotherapy for ovarian cancer: evaluation of optimum schedule for CDDP administration in chronic continuous exposure of ovarian cancer cells to low-dose etoposide in vitro Nihon Sanka Fujinka Gakkai Zasshi 45(2): 125-132
Kagimu, M.; Kaye, S.; Ainomugisha, D.; Lutalo, I.; Walakira, Y.; Guwatudde, D.; Rwabukwali, C. 2012: Evidence-based monitoring and evaluation of the faith-based approach to HIV prevention among Christian and Muslim youth in Wakiso district in Uganda African Health Sciences 12(2): 119-128
Kumagai, M.; Tsunematsu, Y. 2000: Evidence based chemotherapy for pediatric cancers Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(2): 203-220
Sasaki, T.; Maeda, Y.; Kobayashi, T.; Okamoto, R.; Omuro, Y.; Takada, N. 2000: Standard chemotherapy for gastrointestinal malignancies based on evidence Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(2): 166-176
Ozols, R.F.; Young, R.C. 1991: Chemotherapy of ovarian cancer Seminars in Oncology 18(3): 222-232
Nishimura, H.; Imamura, K.; Chang, C. 1996: Chemotherapy for recurrent ovarian cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(9): 1124-1128
Wang, J.; Li, A.J.; Karlan, B.Y. 2002: Chemotherapy in epithelial ovarian cancer Current Women's Health Reports 2(1): 20-26
Paulus, A.; Gennigens, C.; Fillet, G.; Loly, C.; Sautois, B. 2007: Chemotherapy of ovarian cancer: state of the art Revue Medicale de Liege 62(9): 539-547
Ochiai, K. 1994: Tumors. a. Chemotherapy of ovarian cancer Nihon Sanka Fujinka Gakkai Zasshi 46(8): 821-831